Neurogene Inc. in brief
Neurogene Inc. is a listed company in the Pharmaceutical industry, based in Washington, USA. It was founded in 2003. Its last known market value was $30 M (July 2023); there is no current figure. In the year to December 2025 it had sales of $0 M and a net loss of $33 M. It employs about 131 people. Its shares trade under the symbol NGNE (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Neurogene Inc.
Neoleukin Therapeutics is a Advanced Computational method to build entirely new de novo therapeutic proteins to treat serious immunological disorders including cancer and autoimmunity company. The headquarters is in USA.
Neurogene Inc. timeline
- 2003
- 🏁· approximateFounded
- 2007
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2013
- ✎Renamed Aquinox Pharmaceuticals, IncFormerly Aquinox Pharmaceuticals (Usa) Inc.
- 2014
- 🔔· approximateInitial public offering on Nasdaq
- 🔔Initial public offering as Aquinox Pharmaceuticals, IncFinal prospectus filed with the SEC on 7 March 2014; shares registered for exchange trading on 3 March 2014.
- 2019
- ✎Renamed Neoleukin Therapeutics, Inc.Formerly Aquinox Pharmaceuticals, Inc.
- 2023
- ✎Renamed Neurogene Inc.Formerly Neoleukin Therapeutics, Inc..
Events of Neurogene Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,392 (Jan 2020) · #2,618 (Jan 2021) · #3,963 (Jan 2022) · #5,334 (Dec 2022) · #5,009 (Jul 2023)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- -12.5%
- Liabilities / assets
- 8.2%
- Revenue growth
- -96.3%
- R&D / revenue
- 6621.7%
- Revenue per employee
- $0 K
- Profit per employee
- $-253 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-103M | $-90M | — |
| Dec 2024 | $1M | — | $-83M | $-75M | -8167.4% |
| Dec 2023 | — | — | $-56M | $-36M | — |
| Dec 2022 | — | — | $-57M | $-55M | — |
| Dec 2021 | — | — | $-61M | $-61M | — |
| Dec 2020 | — | — | $-34M | $-33M | — |
| Dec 2019 | — | — | $-71M | $-69M | — |
| Dec 2018 | $25M | — | $-33M | $-32M | -126.3% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-77M | $1M | $-78M | $-4.24 | — |
| Dec 2024 | $-71M | $1M | $-71M | $-4.28 | — |
| Dec 2023 | $-51M | $0M | $-52M | — | — |
| Dec 2022 | $-53M | $2M | $-55M | $-1.04 | — |
| Dec 2021 | $-48M | $3M | $-51M | $-1.10 | — |
| Dec 2020 | $-25M | $2M | $-27M | $-0.64 | — |
| Dec 2019 | $-15M | $1M | $-16M | $-2.57 | — |
| Dec 2018 | $-32M | $0M | $-32M | $-1.34 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-29M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations
- Jul 2, 20268-KCurrent reportMaterial agreement · Other events
- Jun 29, 20268-KCurrent reportRegulation FD disclosure · Other events
- Jun 8, 20268-KCurrent reportRegulation FD disclosure
- Jun 4, 20268-KCurrent reportShareholder vote
- May 12, 20268-KCurrent reportResults of operations
- May 12, 202610-QQuarterly report · period to Mar 2026
- Apr 20, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Apr 16, 2026DEF 14AProxy statement
Official filings of Neurogene Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-103 M
- Net income
- $-33 M
For year ending December-2025
Balance sheet
- Total assets
- $289 M
- Total liabilities
- $24 M
- Total equity
- $265 M
As of December-2025
Top 100 institutional investors in Neurogene Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Jennison Associates LLC | 2,229,082 | +1,710,500 (+329.84%) | 10.77% | $62 M | Nov 16, 2026 |
| 2 | Samsara Biocapital, LLC | 1,867,127 | +150,000 (+8.74%) | 9.02% | $52 M | Nov 16, 2026 |
| 3 | Casdin Capital, LLC | 1,585,361 | +40,000 (+2.59%) | 7.66% | $44 M | Nov 16, 2026 |
| 4 | Redmile Group, LLC | 1,562,199 | +150,000 (+10.62%) | 7.55% | $43 M | Nov 16, 2026 |
| 5 | RTW Investments, LP | 1,512,456 | +150,000 (+11.01%) | 7.31% | $42 M | Nov 16, 2026 |
| 6 | BlackRock, Inc. | 1,471,936 | +413,953 (+39.13%) | 7.11% | $41 M | Nov 13, 2026 |
| 7 | EcoR1 Capital, LLC | 1,271,342 | 0 (0.00%) | 6.14% | $35 M | Nov 16, 2026 |
| 8 | Baker Bros. Advisors LP | 991,691 | 0 (0.00%) | 4.79% | $28 M | Nov 16, 2026 |
| 9 | Trails Edge Capital Partners, LP | 964,885 | +250,000 (+34.97%) | 4.66% | $27 M | Nov 16, 2026 |
| 10 | T. Rowe Price Investment Management, Inc. | 850,123 | New | 4.11% | $24 M | Nov 16, 2026 |
| 11 | MPM Bioimpact LLC | 771,839 | New | 3.73% | $21 M | Nov 16, 2026 |
| 12 | Vanguard Capital Management LLC | 711,290 | +174,765 (+32.57%) | 3.44% | $20 M | Nov 13, 2026 |
| 13 | Toronto Dominion Bank | 681,337 | 0 (0.00%) | 3.29% | $19 M | Nov 16, 2026 |
| 14 | Franklin Templeton Inc | 630,859 | +426,579 (+208.82%) | 3.05% | $18 M | Nov 12, 2026 |
| 15 | State Street Corp | 549,269 | +324,947 (+144.86%) | 2.65% | $15 M | Nov 12, 2026 |
| 16 | UBS Group AG | 417,651 | +246,362 (+143.83%) | 2.02% | $12 M | Nov 10, 2026 |
| 17 | Geode Capital Management, LLC | 412,768 | +119,586 (+40.79%) | 1.99% | $11 M | Nov 6, 2026 |
| 18 | FMR LLC | 383,249 | +87,688 (+29.67%) | 1.85% | $11 M | Nov 10, 2026 |
| 19 | ArrowMark Colorado Holdings LLC | 378,829 | +36,376 (+10.62%) | 1.83% | $11 M | Nov 16, 2026 |
| 20 | Tyro Capital Management LLC | 304,401 | New | 1.47% | $8 M | Nov 12, 2026 |
| 21 | Balyasny Asset Management L.P. | 303,994 | -514,712 (-62.87%) | 1.47% | $8 M | Nov 16, 2026 |
| 22 | Great Point Partners LLC | 300,000 | -52,180 (-14.82%) | 1.45% | $8 M | Nov 16, 2026 |
| 23 | Point72 Asset Management, L.P. | 238,967 | +97,047 (+68.38%) | 1.15% | $7 M | Nov 16, 2026 |
| 24 | Morgan Stanley | 221,090 | +29,366 (+15.32%) | 1.07% | $6 M | Nov 13, 2026 |
| 25 | Driehaus Capital Management LLC | 218,528 | +75,000 (+52.25%) | 1.06% | $6 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Jones Hill Capital LP | 217,700 | New | 1.05% | $6 M | Nov 13, 2026 |
| 27 | Integral Health Asset Management, LLC | 200,000 | New | 0.97% | $6 M | Nov 16, 2026 |
| 28 | Moore Capital Management, LP | 181,479 | +39,843 (+28.13%) | 0.88% | $5 M | Nov 16, 2026 |
| 29 | Vanguard Portfolio Management LLC | 174,262 | +78,661 (+82.28%) | 0.84% | $5 M | Nov 13, 2026 |
| 30 | Marshall Wace, LLP | 168,509 | New | 0.81% | $5 M | Nov 13, 2026 |
| 31 | Rock Springs Capital Management LP | 154,401 | +47,651 (+44.64%) | 0.75% | $4 M | Nov 16, 2026 |
| 32 | DAFNA Capital Management LLC | 150,532 | +61,500 (+69.08%) | 0.73% | $4 M | Nov 16, 2026 |
| 33 | Northern Trust Corp | 133,034 | +29,393 (+28.36%) | 0.64% | $4 M | Nov 16, 2026 |
| 34 | Goldman Sachs Group Inc | 121,193 | +19,917 (+19.67%) | 0.59% | $3 M | Nov 16, 2026 |
| 35 | Vestal Point Capital, LP | 115,000 | New | 0.56% | $3 M | Nov 16, 2026 |
| 36 | Deutsche Bank AG\ | 107,949 | +1,289 (+1.21%) | 0.52% | $3 M | Nov 6, 2026 |
| 37 | Vanguard Fiduciary Trust Co | 104,643 | +30,381 (+40.91%) | 0.51% | $3 M | Nov 13, 2026 |
| 38 | Citadel Advisors LLC | 92,858 | -316,124 (-77.30%) | 0.45% | $3 M | Nov 16, 2026 |
| 39 | Dimensional Fund Advisors LP | 87,700 | +55,072 (+168.79%) | 0.42% | $2 M | Nov 4, 2026 |
| 40 | Woodline Partners LP | 83,835 | 0 (0.00%) | 0.41% | $2 M | Nov 16, 2026 |
| 41 | Blair William & Co/il | 79,081 | -67,824 (-46.17%) | 0.38% | $2 M | Nov 10, 2026 |
| 42 | Jpmorgan Chase & Co | 61,953 | +71 (+0.11%) | 0.30% | $2 M | Nov 12, 2026 |
| 43 | Burkehill Global Management, LP | 60,000 | New | 0.29% | $2 M | Nov 16, 2026 |
| 44 | Bank Of America Corp /de/ | 51,171 | +40,047 (+360.01%) | 0.25% | $1 M | Nov 16, 2026 |
| 45 | Charles Schwab Investment Management Inc | 49,589 | +16,847 (+51.45%) | 0.24% | $1 M | Nov 16, 2026 |
| 46 | ADAR1 Capital Management, LLC | 43,800 | +36,000 (+461.54%) | 0.21% | $1 M | Nov 16, 2026 |
| 47 | Trexquant Investment LP | 43,503 | -30,259 (-41.02%) | 0.21% | $1 M | Nov 16, 2026 |
| 48 | Wellington Management Group LLP | 40,732 | +9,339 (+29.75%) | 0.20% | $1 M | Nov 16, 2026 |
| 49 | Bank of New York Mellon Corp | 38,710 | +9,969 (+34.69%) | 0.19% | $1 M | Nov 5, 2026 |
| 50 | Nuveen, LLC | 35,994 | +8,170 (+29.36%) | 0.17% | $1 M | Nov 10, 2026 |
| 51 | Raiffeisen Bank International AG | 34,000 | 0 (0.00%) | 0.16% | $1 M | Oct 28, 2026 |
| 52 | American Century Companies Inc | 30,063 | +6,733 (+28.86%) | 0.15% | $1 M | Nov 12, 2026 |
| 53 | Quadrature Capital Ltd | 27,147 | +2,827 (+11.62%) | 0.13% | $1 M | Nov 13, 2026 |
| 54 | Alps Advisors Inc | 26,528 | +10,488 (+65.39%) | 0.13% | $1 M | Nov 3, 2026 |
| 55 | Millennium Management LLC | 24,633 | -18,101 (-42.36%) | 0.12% | $1 M | Nov 16, 2026 |
| 56 | Informed Momentum Co LLC | 20,426 | New | 0.10% | $1 M | Nov 16, 2026 |
| 57 | TD Asset Management Inc | 20,028 | New | 0.10% | $1 M | Nov 13, 2026 |
| 58 | Rhumbline Advisers | 18,074 | +3,921 (+27.70%) | 0.09% | $1 M | Nov 10, 2026 |
| 59 | SEI Investments Co | 16,758 | New | 0.08% | $0 M | Nov 10, 2026 |
| 60 | Engineers Gate Manager LP | 15,380 | New | 0.07% | $0 M | Nov 16, 2026 |
| 61 | Quantinno Capital Management LP | 15,196 | New | 0.07% | $0 M | Nov 13, 2026 |
| 62 | AQR Capital Management LLC | 15,185 | +124 (+0.82%) | 0.07% | $0 M | Nov 16, 2026 |
| 63 | Creative Planning | 14,933 | +4,352 (+41.13%) | 0.07% | $0 M | Nov 2, 2026 |
| 64 | Seven Fleet Capital Management LP | 14,700 | -7,360 (-33.36%) | 0.07% | $0 M | Nov 16, 2026 |
| 65 | Magnetar Financial LLC | 13,816 | New | 0.07% | $0 M | Nov 13, 2026 |
| 66 | Price T Rowe Associates Inc /MD/ | 12,980 | +4,084 (+45.91%) | 0.06% | $0 M | Nov 16, 2026 |
| 67 | Bridgeway Capital Management, LLC | 12,551 | -6,230 (-33.17%) | 0.06% | $0 M | Nov 16, 2026 |
| 68 | Empowered Funds, LLC | 12,551 | New | 0.06% | $0 M | Nov 13, 2026 |
| 69 | Rafferty Asset Management, LLC | 11,591 | New | 0.06% | $0 M | Nov 13, 2026 |
| 70 | Universal- Beteiligungs- und Servicegesellschaft mbH | 11,047 | New | 0.05% | $0 M | Nov 10, 2026 |
| 71 | Virtus Investment Advisers, LLC | 10,905 | -339 (-3.01%) | 0.05% | $0 M | Nov 12, 2026 |
| 72 | Alliancebernstein L.P. | 10,570 | -3,200 (-23.24%) | 0.05% | $0 M | Nov 16, 2026 |
| 73 | Corient Private Wealth LP | 10,517 | New | 0.05% | $0 M | Nov 16, 2026 |
| 74 | Renaissance Technologies LLC | 10,205 | -10,200 (-49.99%) | 0.05% | $0 M | Nov 12, 2026 |
| 75 | Susquehanna International Group, LLP | 9,887 | New | 0.05% | $0 M | Nov 16, 2026 |
| 76 | Vanguard Global Advisers, LLC | 9,642 | +4,788 (+98.64%) | 0.05% | $0 M | Nov 13, 2026 |
| 77 | Citigroup Inc | 9,629 | +1,761 (+22.38%) | 0.05% | $0 M | Nov 4, 2026 |
| 78 | Susquehanna Portfolio Strategies, LLC | 9,514 | New | 0.05% | $0 M | Nov 16, 2026 |
| 79 | Barclays PLC | 9,427 | +6,117 (+184.80%) | 0.05% | $0 M | Nov 6, 2026 |
| 80 | MetLife Investment Management, LLC | 8,986 | +3,054 (+51.48%) | 0.04% | $0 M | Nov 16, 2026 |
| 81 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 8,420 | +3,213 (+61.71%) | 0.04% | $0 M | Nov 16, 2026 |
| 82 | Keybank National Association/oh | 7,947 | New | 0.04% | $0 M | Nov 4, 2026 |
| 83 | State Board Of Administration Of Florida Retirement System | 7,491 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 84 | XTX Topco Ltd | 7,465 | -47,959 (-86.53%) | 0.04% | $0 M | Nov 16, 2026 |
| 85 | New York State Common Retirement Fund | 7,400 | +3,200 (+76.19%) | 0.04% | $0 M | Nov 17, 2026 |
| 86 | Russell Investments Group, Ltd. | 6,358 | +368 (+6.14%) | 0.03% | $0 M | Nov 6, 2026 |
| 87 | Mitsubishi UFJ Asset Management Co., Ltd. | 6,040 | -50 (-0.82%) | 0.03% | $0 M | Nov 5, 2026 |
| 88 | BNP Paribas Financial Markets | 4,431 | +2,533 (+133.46%) | 0.02% | $0 M | Nov 12, 2026 |
| 89 | Police & Firemen's Retirement System of New Jersey | 4,093 | +247 (+6.42%) | 0.02% | $0 M | Nov 9, 2026 |
| 90 | China Universal Asset Management Co., Ltd. | 3,651 | +1,136 (+45.17%) | 0.02% | $0 M | Oct 28, 2026 |
| 91 | Acadian Asset Management LLC | 3,172 | New | 0.02% | $0 M | Nov 9, 2026 |
| 92 | Tower Research Capital LLC (TRC) | 3,112 | +2,672 (+607.27%) | 0.01% | $0 M | Nov 16, 2026 |
| 93 | Royal Bank Of Canada | 3,074 | +668 (+27.76%) | 0.01% | $0 M | Nov 16, 2026 |
| 94 | Wells Fargo & Company/mn | 3,056 | -6,415 (-67.73%) | 0.01% | $0 M | Nov 16, 2026 |
| 95 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 3,055 | +2,763 (+946.23%) | 0.01% | $0 M | Nov 16, 2026 |
| 96 | Legal & General Group Plc | 1,469 | +371 (+33.79%) | 0.01% | $0 M | Nov 16, 2026 |
| 97 | Jones Financial Companies Lllp | 1,438 | New | 0.01% | $0 M | Nov 13, 2026 |
| 98 | Ameritas Investment Partners, Inc. | 1,401 | +392 (+38.85%) | 0.01% | $0 M | Nov 13, 2026 |
| 99 | Simplex Trading, LLC | 1,190 | New | 0.01% | $0 M | Nov 4, 2026 |
| 100 | Mirae Asset Global Investments Co., Ltd. | 1,023 | +316 (+44.70%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding Neurogene Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 397,791 | $13 M | 1.9% | <0.01% | +4.1% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 296,322 | $9 M | 1.4% | 0.01% | +9.6% | Jun 30, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 218,783 | $7 M | 1.1% | 0.62% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC | 177,200 | $6 M | 0.86% | 0.26% | −27% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 124,026 | $4 M | 0.60% | 0.01% | +11% | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 126,728 | $4 M | 0.61% | <0.01% | +5.1% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 105,167 | $3 M | 0.51% | 0.02% | +9.1% | Jun 30, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 90,867 | $3 M | 0.44% | 0.05% | +17% | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 88,398 | $3 M | 0.43% | 0.03% | −6.6% | Jun 30, 2026 |
| 🇺🇸 Meridian Small Cap Growth FundArrowMark Colorado Holdings, LLC | 75,859 | $2 M | 0.37% | 0.87% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 57,993 | $2 M | 0.28% | <0.01% | +20% | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 55,794 | $2 M | 0.27% | <0.01% | −1.9% | May 31, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 51,100 | $1 M | 0.25% | 0.03% | no change | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 37,552 | $1 M | 0.18% | 0.08% | +32% | Jun 30, 2026 |
| 🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC | 36,199 | $1 M | 0.17% | 0.11% | no change | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 27,503 | $1 M | 0.13% | 0.01% | +11% | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 20,627 | $1 M | 0.10% | 0.01% | +23% | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 18,781 | $1 M | 0.09% | 0.40% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 20,446 | $1 M | 0.10% | 0.02% | +24% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 18,774 | $1 M | 0.09% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 15,827 | $0 M | 0.08% | 0.02% | +13% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 15,005 | $0 M | 0.07% | 0.01% | +21% | Jul 31, 2026 |
| 🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc. | 15,498 | $0 M | 0.07% | 0.04% | −6.7% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 16,206 | $0 M | 0.08% | <0.01% | +5.7% | May 31, 2026 |
| 🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc. | 15,968 | $0 M | 0.08% | 0.28% | +16% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 12,679 | $0 M | 0.06% | <0.01% | +51% | Jul 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 12,271 | $0 M | 0.06% | <0.01% | +1602% | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 11,896 | $0 M | 0.06% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc. | 9,770 | $0 M | 0.05% | 0.02% | −5.8% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 9,344 | $0 M | 0.05% | 0.03% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 10,287 | $0 M | 0.05% | <0.01% | +31% | May 31, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 8,852 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 8,240 | $0 M | 0.04% | 0.01% | +24% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 8,684 | $0 M | 0.04% | 0.02% | +21% | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 7,100 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 6,409 | $0 M | 0.03% | <0.01% | −12% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 5,853 | $0 M | 0.03% | <0.01% | +4.6% | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 5,675 | $0 M | 0.03% | 0.01% | −3.1% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 5,645 | $0 M | 0.03% | <0.01% | +19% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 5,395 | $0 M | 0.03% | 0.01% | +11% | Jul 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 5,239 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 4,657 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 4,530 | $0 M | 0.02% | <0.01% | +55% | Jun 30, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 4,300 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 4,401 | $0 M | 0.02% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 4,065 | $0 M | 0.02% | <0.01% | +4.1% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 3,984 | $0 M | 0.02% | <0.01% | +93% | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 3,800 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Nationwide Bailard Small Cap Value FundNATIONWIDE FUND ADVISORS | 3,625 | $0 M | 0.02% | 0.09% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 4,187 | $0 M | 0.02% | <0.01% | +5.4% | May 31, 2026 |
| 🇺🇸 LVIP JPMorgan Small Cap Core FundLincoln Financial Investments Corporation | 3,459 | $0 M | 0.02% | 0.05% | −5.3% | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 3,411 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 3,321 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 3,044 | $0 M | 0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 2,687 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 2,787 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 2,530 | $0 M | 0.01% | 0.04% | +26% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 2,444 | $0 M | 0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC | 2,403 | $0 M | 0.01% | 0.02% | −14% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 2,356 | $0 M | 0.01% | 0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 2,329 | $0 M | 0.01% | 0.02% | −4.5% | Jun 30, 2026 |
| 🇺🇸 Vy Jpmorgan Small Cap Core Equity PortfolioVoya Investments, LLC | 2,276 | $0 M | 0.01% | 0.02% | −5.0% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 1,907 | $0 M | <0.01% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company | 1,990 | $0 M | <0.01% | 0.02% | new | May 31, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 1,710 | $0 M | <0.01% | 0.01% | +5.2% | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 1,776 | $0 M | <0.01% | 0.01% | +12% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 1,645 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 1,706 | $0 M | <0.01% | 0.01% | +56% | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 1,663 | $0 M | <0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 1,626 | $0 M | <0.01% | <0.01% | −31% | Jun 30, 2026 |
| 🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP | 1,506 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 1,700 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 1,520 | $0 M | <0.01% | 0.01% | +21% | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 1,449 | $0 M | <0.01% | <0.01% | +3.0% | Jul 31, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 1,381 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Siit Small Cap II FundSEI INVESTMENTS MANAGEMENT CORPORATION | 1,558 | $0 M | <0.01% | 0.02% | no change | May 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 1,290 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Siit Small Cap FundSEI INVESTMENTS MANAGEMENT CORPORATION | 1,400 | $0 M | <0.01% | 0.02% | no change | May 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 1,186 | $0 M | <0.01% | 0.01% | +1.9% | Jul 31, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 1,070 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 1,023 | $0 M | <0.01% | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 SIMT Small Cap FundSEI Institutional Managed Trust | 1,060 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 1,009 | $0 M | <0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 938 | $0 M | <0.01% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust | 1,009 | $0 M | <0.01% | 0.02% | no change | May 31, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 796 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 815 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 809 | $0 M | <0.01% | 0.01% | +11% | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 776 | $0 M | <0.01% | <0.01% | +10% | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 716 | $0 M | <0.01% | <0.01% | +83% | Jul 31, 2026 |
| 🇺🇸 SA Multi-Managed Small Cap PortfolioSunAmerica Asset Management, LLC | 730 | $0 M | <0.01% | 0.02% | −9.1% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 722 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 571 | $0 M | <0.01% | <0.01% | +17% | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 531 | $0 M | <0.01% | <0.01% | +24% | May 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 477 | $0 M | <0.01% | <0.01% | −41% | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 445 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional US Vector Equity ETFDimensional Fund Advisors LP | 400 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC | 400 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 420 | $0 M | <0.01% | <0.01% | −31% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 416 | $0 M | <0.01% | <0.01% | −32% | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Neurogene Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Rachel McMinnChief Executive Officer, Director | Option exercise | +756 | $25.32 | $19 K | 1.35 M | Form 4 |
| filed | Christine Mikail CvijicPresident and CFO, Director | Sell10b5-1 plan | -4,200 | $36.13 | $152 K | 84,040 | Form 4 |
| filed | Christine Mikail CvijicPresident and CFO, Director | Sell10b5-1 plan | -600 | $36.02 | $22 K | 88,240 | Form 4 |
| filed | Christine Mikail CvijicPresident and CFO, Director | Sell10b5-1 plan | -2,531 | $34.58 | $88 K | 90,370 | Form 4 |
| filed | Christine Mikail CvijicPresident and CFO, Director | Sell10b5-1 plan | -1,530 | $35.23 | $54 K | 88,840 | Form 4 |
| filed | Christine Mikail CvijicPresident and CFO, Director | Sell10b5-1 plan | -739 | $34.06 | $25 K | 92,901 | Form 4 |
| filed | Christine Mikail CvijicPresident and CFO, Director | Sell10b5-1 plan | -4,800 | $30.07 | $144 K | 98,440 | Form 4 |
| filed | Christine Mikail CvijicPresident and CFO, Director | Sell10b5-1 plan | -4,800 | $32.44 | $156 K | 93,640 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Neurogene Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-4 reverse split ; 1-for-5 reverse split ; 1-for-19.19 reverse split in the period to ; 1-for-19.2 reverse split
Fails to deliver
- : 6 shares at $28.82
- : 11,639 shares at $30.42
- : 6 shares at $26.99
- : 88 shares at $21.56
- : 20 shares at $24.44
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Neurogene Inc. scorecard#
Passes 1 of the 8 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-4.24 vs -4.28Diluted EPS -4.24 in fiscal 2025 against -4.28 the year before (report's currency).
- ✗Net income higher than five years earlier-$90 M-$90 M in fiscal 2025 against -$33 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$90 MNet income -$90 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-31.4%-31.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities16.6×Current ratio 16.56 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year21.4%Diluted shares up 21.4% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Neurogene Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0−100%— | 0.9—100% | 0—— | — | — | — | — | 25—100% | — | — | |
| Research and development | 75+23.1%— | 61+37.2%6586% | 44−6.5%— | 48r41+21.3%— | 39+60.9%— | 24+451%— | 4.4−89.4%— | 42+15.2%167% | 36+27.8%— | 28—— | |
| General and administrative | 28+25.2%— | 23+102%2445% | 11+24.2%— | 9.0r18−58.2%— | 22+25.1%— | 17−8.6%— | 19+18.9%— | 16+6.6%63.3% | 15+60.3%— | 9.3—— | |
| Operating expenses | 103+23.7%— | 84+50.3%9030% | 56−1.7%— | 57r59−6.9%— | 61—— | — | 71+23.1%— | 58+12.7%230% | 51+35.8%— | 38—— | |
| Operating income | −103—— | −83—−8930% | −56—— | −57r−59—— | −61—— | −34—— | −71—— | −33—−130% | −51—— | −38—— | |
| Interest and finance income | 12+36.4%— | 8.5+187%915% | 3.0+121%— | 1.3—— | — | — | — | — | — | — | |
| Interest expense and finance costs | 0.0−58.3%— | 0.00.0%1.3% | 0.0+500%— | 0.0—— | — | — | 0.0−75.0%— | 0.00.0%0.0% | 0.0+300%— | 0.0—— | |
| Net interest income | — | — | — | 1.6+8226%— | 0.0—— | — | — | — | — | — | |
| Other non-operating income (expense) | 13+73.9%— | 7.5—807% | — | −0.0—— | −0.0r0.0−103%— | 0.5−70.3%— | 1.5+46.0%— | 1.0+11.0%4.2% | 0.9+45.6%— | 0.6—— | |
| Income before tax | −90—— | −75—−8124% | −36—— | −55r−58—— | −61—— | −33—— | −69—— | −32—−126% | −50—— | −37—— | |
| Income tax | 0—— | 0—0.0% | — | — | — | — | — | — | — | 0—— | |
| Net income including minority interests | — | — | — | — | — | — | −69—— | −32—−126% | −50—— | −37—— | |
| Net income attributable to shareholders | −90—— | −75—−8124% | −36—— | −55r−58—— | −61—— | −33—— | −69—— | −32—−126% | −50—— | −37—— | |
| Earnings per share, basic | -4.24—— | -4.28—— | — | -1.04—— | -1.10—— | -0.64—— | -2.57—— | -1.34—— | -2.14—— | -1.96—— | |
| Earnings per share, diluted | -4.24—— | -4.28—— | — | -1.04—— | -1.10—— | -0.64—— | -2.57—— | -1.34—— | -2.14—— | -1.96—— | |
| Shares, weighted average (basic) | 21+21.4%— | 18—— | — | 55+0.3%— | 55+6.2%— | 52—— | — | — | — | — | |
| Shares, weighted average (diluted) | 21+21.4%— | 18—— | — | 55+0.3%— | 55+6.2%— | 52+91.7%— | 27+14.9%— | 24+0.3%— | 23+24.1%— | 19—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 104−24.0%36.0% | 137−7.8%40.7% | 148+80.7%66.6% | 82r38−42.4%75.1% | 142−26.0%87.3% | 193+34.6%91.5% | 143+86.0%97.3% | 77+47.8%99.1% | 52+61.1%47.2% | 32—20.9% | |
| Short-term investments | 165−6.1%57.2% | 176+259%52.4% | 49—22.0% | 0r58—0.0% | 0—0.0% | — | — | — | — | — | |
| Other current assets | 0.2−82.9%0.1% | 1.0−10.4%0.3% | 1.1+73.8%0.5% | 0.6r2.8−58.6%0.6% | 1.5−22.6%0.9% | 2.0+291%0.9% | 0.5—0.3% | — | — | — | |
| Current assets | 272−14.0%94.2% | 316+57.7%94.1% | 200+136%90.0% | 85r99−41.2%77.5% | 144−26.0%88.2% | 195+35.5%92.4% | 144+86.1%97.7% | 77−29.1%99.4% | 109+5.2%98.6% | 103—67.0% | |
| Property, plant and equipment | 13−17.1%4.4% | 15−10.2%4.6% | 17−14.6%7.7% | 20r6.2+212%18.4% | 6.5+80.7%4.0% | 3.6+73.3%1.7% | 2.1+415%1.4% | 0.4−55.8%0.5% | 0.9+6.6%0.8% | 0.8—0.5% | |
| Right-of-use (leased) assets | 2.6−11.7%0.9% | 3.0−18.5%0.9% | 3.7−15.3%1.7% | 4.3r9.7−59.7%4.0% | 11+6.0%6.6% | 10+1219%4.8% | 0.8—0.5% | — | — | — | |
| Other intangible assets | — | — | — | 0−100%0.0% | 0.1−63.1%0.1% | 0.3−38.8%0.2% | 0.6—0.4% | — | — | — | |
| Total assets | 289−14.0%100% | 336+50.8%100% | 223+104%100% | 109r116−33.1%100% | 163−22.4%100% | 211+43.2%100% | 147+89.4%100% | 78−29.6%100% | 110−28.5%100% | 154—100% | |
| Accounts payable | 2.0+46.2%0.7% | 1.3−48.5%0.4% | 2.6+315%1.2% | 0.6r0.5+18.8%0.6% | 0.5r0.5−60.2%0.3% | 1.3r1.3−17.5%0.6% | 1.6r1.6+128%1.1% | 0.7−88.3%0.9% | 6.0−12.3%5.5% | 6.9—4.4% | |
| Current liabilities | 16+8.3%5.7% | 15−34.0%4.5% | 23+245%10.3% | 6.7r11−23.0%6.1% | 8.6+9.5%5.3% | 7.9+66.3%3.7% | 4.7+2.5%3.2% | 4.6−57.8%6.0% | 11+15.1%9.9% | 9.5—6.2% | |
| Lease liabilities (non-current) | 6.8−27.4%2.4% | 9.4−23.6%2.8% | 12+214%5.5% | 3.9r10−66.5%3.6% | 12+3.4%7.2% | 11+2429%5.4% | 0.4—0.3% | — | — | — | |
| Total liabilities | 24−6.5%8.2% | 25−30.6%7.6% | 37+244%16.4% | 11r22−47.9%9.7% | 20+5.7%12.5% | 19+262%9.2% | 5.3+7.9%3.6% | 4.9−56.8%6.4% | 11+17.8%10.4% | 9.7—6.3% | |
| Retained earnings | −353—−122% | −262—−78.1% | −187—−84.1% | −151r−451—−138% | −393—−241% | −333—−158% | −300—−204% | −230—−296% | −199—−180% | −148—−96.0% | |
| Shareholders' equity | 265−14.7%91.8% | 310+66.8%92.4% | 186—83.6% | −146r94—−133% | −92r143−148%−56.3% | 191+35.0%90.8% | 142+95.0%96.4% | 73−26.5%93.6% | 99−31.6%89.6% | 145—93.7% | |
| Total liabilities and equity | 289−14.0%100% | 336+50.8%100% | 223+104%100% | 109r116−33.1%100% | 163−22.4%100% | 211+43.2%100% | 147+89.4%100% | 78−29.6%100% | 110−28.5%100% | 154—100% | |
| Shares outstanding | 15+4.3%— | 15+15.8%— | 13—— | — | 42+0.6%— | 42+11.1%— | 38+61.4%— | 24+0.3%— | 23+0.2%— | 23—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 3.0−4.8%— | 3.2−2.1%345% | 3.3+2.1%— | 3.2r1.6+145%— | 1.3+66.4%— | 0.8+131%— | 0.3+17.6%— | 0.3−19.7%1.2% | 0.4—— | — | |
| Share-based compensation | 14+70.5%— | 8.3+487%899% | 1.4+13.3%— | 1.3r8.8−89.2%— | 12+106%— | 5.6−26.8%— | 7.7+63.5%— | 4.7+22.4%18.8% | 3.8+95.3%— | 2.0—— | |
| Cash from operating activities | −77—— | −71—−7633% | −51—— | −53r−46—— | −48—— | −25—— | −15—— | −32—−126% | −45—— | −30—— | |
| Capital expenditure | −1.2—— | −0.8—−87.4% | −0.3—— | −2.2r−1.1—— | −3.3—— | −2.2—— | −0.9—— | −0.0—−0.2% | −0.5—— | −0.7—— | |
| Cash from investing activities | 14—— | −125−589%−13542% | 26—— | −2.2r−59—— | −3.3—— | −2.2—— | −0.7−101%— | 56−12.6%224% | 64—— | −48—— | |
| Shares issued | 30—— | 0−100%0.0% | 92—— | 0—— | 0−100%— | 72−11.6%— | 81r86—— | — | — | 75—— | |
| Cash from financing activities | 30−83.5%— | 184+99.0%19900% | 92+39.0%— | 67r0.2+8989%— | 0.7−99.1%— | 77−6.2%— | 82+14328%— | 0.6+34.8%2.3% | 0.4−99.4%— | 71—— | |
| Exchange-rate effect on cash | — | — | — | — | — | 0−100%— | 0.0—— | −0.0−420%−0.2% | 0.0—— | −0.1—— | |
| Change in cash | −33—— | −12−118%−1275% | 67+481%— | 11r−105—— | −50−199%— | 50−23.9%— | 66+166%— | 25+26.2%99.6% | 20—— | −7.2—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | 0*—— | 0—— | 0−100%— | — | 0*—— | 0—— | 0.9—100% | — | 0*—— | |
| Research and development | 95+36.0%— | 24+36.4%— | 25+31.5%— | 25+41.6%— | 21*+34.5%— | 17+5.9%— | 19+23.0%— | 18+31.2%— | 15*+26.0%— | 16—— | 16—1702% | 14—— | 12r37*—— | |
| General and administrative | 35+27.4%— | 8.9+35.0%— | 11+66.8%— | 8.2+0.5%— | 6.9*+11.8%— | 6.6+11.2%— | 6.7+26.3%— | 8.2+55.8%— | 6.2*+142%— | 5.9—— | 5.3—575% | 5.2—— | 2.5*—— | |
| Operating expenses | 130+33.5%— | 32+36.0%— | 37+40.6%— | 33+28.7%— | 28*+28.0%— | 24+7.3%— | 26+23.8%— | 26+38.0%— | 22*+46.0%— | 22—— | 21—2277% | 19—— | 15r32*—— | |
| Operating income | −130—— | −32—— | −37—— | −33—— | −28*—— | −24—— | −26—— | −26—— | −22*—— | −22—— | −20—−2177% | −19—— | −15r−32*—— | |
| Interest and finance income | 10−8.3%— | 3.2+18.2%— | 2.0−30.1%— | 2.3−29.5%— | 2.7*+17.8%— | 2.7+48.7%— | 2.9+43.9%— | 3.2+38.2%— | 2.3*+191%— | 1.8—— | 2.0—220% | 2.3—— | 0.8*—— | |
| Interest expense and finance costs | 0.0−83.3%— | 0−100%— | 0−100%— | 0−100%— | 0.0*−50.0%— | 0.0−66.7%— | 0.0−75.0%— | 0.0−33.3%— | 0.0*−33.3%— | 0.0—— | 0.0—0.4% | 0.0—— | 0.0*—— | |
| Net income attributable to shareholders | −119—— | −29—— | −34—— | −31—— | −25*—— | −21—— | −22—— | −23—— | −20*−919%— | −20—— | −18—−1999% | −17—— | 2.4r−16*—— | |
| Earnings per share, basic | — | -1.05—— | -1.53—— | -1.39—— | — | -0.99—— | -1.05—— | -1.08—— | — | -1.19—— | -1.09—— | -1.00—— | — | |
| Earnings per share, diluted | — | -1.05—— | -1.53—— | -1.39—— | — | -0.99—— | -1.05—— | -1.08—— | — | -1.19—— | -1.09—— | -1.00—— | — | |
| Shares, weighted average (basic) | 28+30.8%— | 28+30.8%— | 23+7.1%— | 22+6.2%— | — | 21+24.9%— | 21+24.3%— | 21+24.2%— | — | 17—— | 17—— | 17—— | — | |
| Shares, weighted average (diluted) | 28+30.8%— | 28+30.8%— | 23+7.1%— | 22+6.2%— | — | 21+24.9%— | 21+24.3%— | 21+24.2%— | — | 17—— | 17—— | 17—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 79—20.9% | 79+11.2%20.9% | 112+91.3%46.0% | 124+75.4%47.2% | 104−24.0%36.0% | 71+6.6%24.7% | 59−47.0%19.8% | 71−52.9%22.4% | 137−7.8%40.7% | 67—40.6% | 111—61.7% | 150—76.9% | 148—66.6% | |
| Short-term investments | 281—74.3% | 281+44.4%74.3% | 113−47.7%46.2% | 119−46.3%45.2% | 165−6.1%57.2% | 194+169%67.5% | 216+403%72.6% | 222+1044%70.4% | 176+259%52.4% | 72—44.1% | 43—23.8% | 19—9.9% | 49—22.0% | |
| Other current assets | 0.1—0.0% | 0.1−41.3%0.0% | 0.1−86.4%0.1% | 0.2−81.8%0.1% | 0.2−82.9%0.1% | 0.2−87.0%0.1% | 1.0−36.6%0.3% | 1.0−20.5%0.3% | 1.0−10.4%0.3% | 1.6—1.0% | 1.5—0.9% | 1.3—0.6% | 1.1—0.5% | |
| Current assets | 363—96.0% | 363+34.1%96.0% | 229−17.9%93.7% | 247−16.8%93.8% | 272−14.0%94.2% | 271+88.3%94.0% | 279+75.3%93.8% | 296+70.2%94.0% | 316+57.7%94.1% | 144—87.5% | 159—88.5% | 174—89.1% | 200—90.0% | |
| Property, plant and equipment | 11—3.0% | 11−17.0%3.0% | 12−17.7%4.8% | 13−15.6%4.8% | 13−17.1%4.4% | 13−16.1%4.7% | 14−11.3%4.8% | 15−10.1%4.7% | 15−10.2%4.6% | 16—9.8% | 16—8.9% | 16—8.4% | 17—7.7% | |
| Right-of-use (leased) assets | 2.1—0.5% | 2.1−13.8%0.5% | 2.3−13.0%0.9% | 2.5−12.3%0.9% | 2.6−11.7%0.9% | 2.4−25.0%0.8% | 2.6−23.1%0.9% | 2.8−21.4%0.9% | 3.0−18.5%0.9% | 3.2—1.9% | 3.4—1.9% | 3.6—1.8% | 3.7—1.7% | |
| Total assets | 378—100% | 378+31.3%100% | 244−17.8%100% | 263−16.5%100% | 289−14.0%100% | 288+75.4%100% | 297+65.3%100% | 315+61.4%100% | 336+50.8%100% | 164—100% | 180—100% | 195—100% | 223—100% | |
| Accounts payable | 2.3—0.6% | 2.3+48.2%0.6% | 3.3+59.9%1.3% | 4.7+53.0%1.8% | 2.0+46.2%0.7% | 1.5−8.3%0.5% | 2.1+19.5%0.7% | 3.1+101%1.0% | 1.3−48.5%0.4% | 1.7—1.0% | 1.7—1.0% | 1.5—0.8% | 2.6—1.2% | |
| Current liabilities | 18—4.8% | 18+23.5%4.8% | 22+39.3%8.8% | 19+33.9%7.2% | 16+8.3%5.7% | 15−6.9%5.1% | 15+18.1%5.2% | 14+19.3%4.5% | 15−34.0%4.5% | 16—9.6% | 13—7.3% | 12—6.0% | 23—10.3% | |
| Lease liabilities (non-current) | 4.5—1.2% | 4.5−36.1%1.2% | 5.3−32.0%2.2% | 6.1−29.4%2.3% | 6.8−27.4%2.4% | 7.1−30.2%2.5% | 7.8−28.3%2.6% | 8.6−26.1%2.7% | 9.4−23.6%2.8% | 10—6.2% | 11—6.1% | 12—6.0% | 12—5.5% | |
| Total liabilities | 23—6.1% | 23+3.7%6.1% | 27+13.2%11.1% | 25+7.9%9.6% | 24−6.5%8.2% | 22−16.5%7.7% | 24−3.0%8.1% | 24−4.3%7.5% | 25−30.6%7.6% | 27—16.3% | 25—13.8% | 25—12.6% | 37—16.4% | |
| Retained earnings | −447—−118% | −447—−118% | −418—−171% | −384—−146% | −353—−122% | −328—−114% | −307—−103% | −285—−90.4% | −262—−78.1% | −243—−148% | −223—−124% | −204—−104% | −187—−84.1% | |
| Shareholders' equity | 355—93.9% | 355+33.6%93.9% | 217−20.5%88.9% | 238−18.5%90.4% | 265−14.7%91.8% | 266+93.2%92.3% | 273+76.3%91.9% | 292+70.9%92.5% | 310+66.8%92.4% | 137—83.7% | 155—86.2% | 171—87.4% | 186—83.6% | |
| Total liabilities and equity | 378—100% | 378+31.3%100% | 244−17.8%100% | 263−16.5%100% | 289−14.0%100% | 288+75.4%100% | 297+65.3%100% | 315+61.4%100% | 336+50.8%100% | 164—100% | 180—100% | 195—100% | 223—100% | |
| Shares outstanding | 21—— | 21+40.1%— | 16+10.9%— | 16+4.6%— | 15+4.3%— | 15+13.6%— | 14+9.9%— | 15+16.1%— | 15+15.8%— | 13—— | 13—— | 13—— | 13—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 3.3+3.9%— | 0.8*+2.6%— | 0.8*+1.6%— | 0.8+13.1%— | 0.8*−1.1%— | 0.80.0%— | 0.80.0%— | 0.7−8.0%— | 0.8*−3.9%— | 0.8—— | 0.8—86.5% | 0.8—— | 0.8r2.8*—— | |
| Share-based compensation | 20+50.3%— | 5.1+53.0%— | 7.9+131%— | 3.6−10.4%— | 3.4*+35.2%— | 3.4+36.0%— | 3.4+47.3%— | 4.0+287%— | 2.5*+601%— | 2.5—— | 2.3—250% | 1.0—— | 0.4*—— | |
| Cash from operating activities | −96—— | −29*—— | −24*—— | −26—— | −17*—— | −20*—— | −19*—— | −21—— | −17*—— | −16*—— | −16*—−1718% | −22—— | −17r−30*—— | |
| Capital expenditure | −1.1—— | −0.3*—— | −0.4*—— | −0.3—— | −0.1*—— | −0.1*—— | −0.1*—— | −0.8—— | −0.1*—— | −0.2*—— | −0.5*—−49.7% | −0.1—— | −0.1*—— | |
| Cash from investing activities | −84—— | −166*−855%— | 6.1*−18.1%— | 46—— | 30*—— | 22*—— | 7.5*—— | −45−250%— | −103*−497%— | −29*—— | −24*—−2553% | 30—— | 26r17*—— | |
| Shares issued | — | 0*—— | — | — | 30r21*—— | 0r9.8*—— | — | — | 0*—— | — | — | — | — | |
| Cash from financing activities | 188−5.7%— | 162*+1564%— | 6.0*+10976%— | 0.2+4775%— | 21*−89.1%— | 9.7*+7312%— | 0.1*−86.5%— | 0.0—— | 190*+102%— | 0.1*—— | 0.4*—43.1% | −6.5—— | 94r93*—— | |
| Change in cash | 7.9+81.5%— | −34*−375%— | −12*—— | 20—— | 33*−53.1%— | 12*—— | −12*—— | −66−3837%— | 70*−32.2%— | −44*—— | −39*—−4228% | 1.8—— | 103r80*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Neurogene Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Chief executive | $3.2 M | $3.2 M | $2.1 M | $202 |
| 2024Chief executive | $3.5 M | $2.7 M | $2.9 M | $225 |
| 2023Chief executive | $1.8 M | $1.9 M | $1.2 M | $190 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Neurogene Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 2 · Material agreement 3 · Unregistered share sale 1 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
5 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2013 | $14 M | No. 5 | $10 to $50 million | 7 | equity, options | SEC |
| Sep 2011 | $4 M | No. 4 | $2 to $10 million | 6 | equity, options | SEC |
| Jan 2011 | $5 M | No. 3 | $2 to $10 million | 6 | equity, options | SEC |
| Jun 2010 | $4 M | No. 2 | $2 to $10 million | 1 | equity, options | SEC |
| Mar 2010 | $5 M | No. 1 | $2 to $10 million | 5 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Neurogene Inc.#
1 labor condition applications certified in fiscal 2020 for 1 positions, at a median wage of $110 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Production Planner/SchedulerLogisticians | 1 | $110 K |
Where: Houston, TX 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Neurogene Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2018 | · | · | · | · | · | · | 30 | · | · | · | · | · | 30 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 70% of workforce | Restructuring planSEC 8-K | “(the "Company") approved a reduction in force of the Company's workforce by approximately 70% and a re-prioritization of the Company’s focus to seek strategic alternatives to maxim…” | Filing | |
| 30 people | Restructuring planSEC 8-K | “Under this plan, the Company reduced its workforce by 30 employees (approximately 53%) and closed its office in San Bruno, California.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Neurogene Inc. compares in Pharmaceutical
- Revenue$0 M · higher than 0% of 324
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Neurogene Inc.🇺🇸 | $30 M | — | — | — |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Eli Lilly and Company$1.20 T
- Johnson & Johnson$652.5 B
- AbbVie Inc.$514.0 B
- Roche Holding AG$370.3 B
- Merck & Co., Inc.$359.8 B
- Novartis AG$286.8 B
Sources and freshness
- Market cap:
- Jul 30, 2023 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 16, 2026
- Profile updated:
- Nov 16, 2026
Figures from value.today research.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Neurogene Inc.? Verify and update this profile — free
Show Neurogene Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.